Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Extention (OLE) Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Patients with IgA Nephropathy Who Have Completed Study Nef-301 in China

Next Previous
Trial Profile

An Open-label Extention (OLE) Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Patients with IgA Nephropathy Who Have Completed Study Nef-301 in China

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budesonide (Primary)
  • Indications IgA nephropathy
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Everest Medicines

Most Recent Events

  • 12 Nov 2024 Status changed from active, no longer recruiting to completed.
  • 28 Aug 2024 According to Everest Medicines media release, topline results from open label study of NEFECON in China, are expected in 2H 2024.
  • 27 Mar 2024 According to Everest Medicines media release, the company expect to report results in 3Q 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top